UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q

For the quarterly period ended December 31, 2000
OR



|New York                                                        | 11-2209324                          
|--------------------------------------------------------------- | ------------------------------------
|(State or other jurisdiction of 
Incorporation or organization) | (I.R.S. Employer
Identification No.)
|                                                                |                                     
|11711 West 79th StreetLenexa, Kansas                            | 66214                               
|(Address of principal executive offices                         | Zip code                            

(913) 307-1000

Indicate by check mark whether the registrant (1) has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  X   No

As of February 9, 2001, there were 7,168,170 shares of Common Stock, $0.10 par value, of the registrant outstanding.





MEDIWARE INFORMATION SYSTEMS, INC. 
INDEX



|PART I         | Financial Information                                                                                            | Page
|-------------- | ---------------------------------------------------------------------------------------------------------------- | ----
|               |                                                                                                                  |     
|ITEM 1.        | Financial Statements
Consolidated Balance Sheets as of December 31, 2000
(Unaudited) and June 30, 2000 (Audited) | 3   
|               | Consolidated Statements of Operations
For the Three and Six Months Ended December 31, 2000 and 1999 (Unaudited)  | 4   
|               | Consolidated Statement of Cash Flows
For the Six Months Ended December 31, 2000 and 1999 (Unaudited)             | 5   
|               | Notes to Financial Statements                                                                                    | 6   
|               | Independent Accountants' Report                                                                                  | 8   
|ITEM 2.        | Management's Discussion and Analysis of Financial
Condition and Results of Operations                            | 9   
|ITEM 3.        | Quantitative and Qualitative Disclosures About Market Risks                                                      | 11  
|ITEM 5         | Other Information                                                                                                | 12  
|ITEM 6.        | Exhibits and Reports on Form 8-K                                                                                 |     
|Signature Page |                                                                                                                  | 13  





# 

---

MEDIWARE
        INFORMATION SYSTEMS, INC. AND SUBSIDIARIESCONSOLIDATED
        BALANCE SHEETS(Amounts
        in thousands except shares)December
        31,
      
      June
        30,2000
      
      2000(Unaudited)
      
      (Audited)ASSETSCurrent AssetsCash and cash
        equivalents
      $
      1,102
      $
      3,634Accounts
        receivable (net of allowance of $600 atDecember 31, 2000 and $518 at June 30, 2000)
      
      6,226
      
      5,880Inventories
      
      192
      
      214Prepaid
        expenses and other current assets
      
    
    227
    350Total current assets
      
      7,747
      
      10,078Fixed assets, net
    2,141
    
    2,194Capitalized software
        costs, net
      
      9,163
      
      7,770Goodwill, net
      
      5,488
      
      5,720Purchased
        technology, net
      
      1,480
      
      1,684Deferred tax asset
      
      2,225
      
      1,454Other long term
        assets
      
      145
      
      151Total Assets
      $
      28,389
      $
      29,051========
      
      ========LIABILITIES AND STOCKHOLDERS' EQUITYCurrent LiabilitiesAccounts
        payable
      $
      1,156
      $
      1,259Advances from
        customers
      
      6,891
      
      6,220Accrued
        expenses and other current liabilities
      
      3,672
      
      3,942Total current liabilities
      
      11,719
      
      11,421Notes payable and accrued interest payable to a related
      party
    1,269
    
    1,236Total liabilities
      
      12,988
      
      12,657Stockholders' EquityPreferred
        stock, $.01 par value; authorized 10,000,000shares; none
        issued or outstanding
      
      -
      
      -Common stock,
        $.10 par value; authorized 12,000,000shares;
        issued and outstanding; 7,166,000 shares atDecember 31,
        2000 and 7,088,000 at June 30, 2000
      
      717
      
      709Additional
        paid-in capital
      
      22,935
      
      22,764Accumulated
        deficit
      
      (8,211)
      
      (7,055)Accumulated
        other comprehensive (loss)
      
      (40)
      
      (24)Total stockholders' equity
      
      15,401
      
      16,394Total Liabilities and Stockholders' Equity
      $
      28,389
      $
      29,051


---

---

MEDIWARE
        INFORMATION SYSTEMS, INC. AND SUBSIDIARIESCONSOLIDATED
        STATEMENT OF OPERATIONS AND COMPREHENSIVE INCOME(Unaudited)(Amounts in
        thousands, except per share amounts)Three Months Ended December
        31,
      
      
      Six Months Ended December
        31,2000
      
      1999
      
      
      2000
      
      1999RevenuesSystem sales
      $
      1,832
      $
      2,062
      
      $
      3,437
      $
      4,384Services
      
      4,217
      
      4,992
      
      
      8,736
      
      9,673Total revenues
      
      6,049
      
      7,054
      
      
      12,173
      
      14,057Cost and ExpensesCost of
        systems
      
      542
      
      843
      
      
      989
      
      1,555Cost of
        services
      
      1,694
      
      1,522
      
      
      3,360
      
      3,099Software
        development costs
      
      1,315
      
      989
      
      
      2,731
      
      2,111Selling,
        general and administrative
      
      3,916
      
      3,034
      
      
      7,047
      
      6,079Total costs
        and expenses
      
      7,467
      
      6,388
      
      
      14,127
      
      12,844Operating
        income (loss)
      
      (1,418)
      
      666
      
      
      (1,954)
      
      1,213Interest and
        other income
      
      24
      
      28
      
      
      59
      
      66Interest (expense)
      
      (16)
      
      (17)
      
      
      (32)
      
      (37)Earnings
        (loss) before provision for income taxes
      
      (1,410)
      
      677
      
      
      (1,927)
      
      1,242Benefit (provision) for income
      taxes
    564
    
    (244)
    
    
    771
    
    (448)Net
        Earnings (Loss)
      
      (846)
      
      433
      
      
      (1,156)
      
      794Other Comprehensive Income, net of
      taxForeign
        currency translation adjustment
      
      -
      
      (15)
      
      
      (16)
      
      (27)Comprehensive
        Income (Loss)
      $
      (846)
      $
      418
      
      $
      (1,172)
      $
      767=======
      
      ======
      
      
      =======
      
      ======Earnings (Loss) Per Common ShareBasic
      $
      (0.12)
      $
      0.07
      
      $
      (0.16)
      $
      0.13=======
      
      ======
      
      
      =======
      
      ======Diluted
      $
      (0.12)
      $
      0.06
      
      $
      (0.16)
      $
      0.11=======
      
      ======
      
      
      =======
      
      ======Weighted Average Common Shares
      OutstandingBasic
      
      7,166
      
      6,344
      
      
      7,141
      
      6,258=======
      
      ======
      
      
      =======
      
      ======Diluted
      
      7,166
      
      7,201
      
      
      7,141
      
      7,176=======
      
      ======
      
      
      =======
      
      ======


---

---

MEDIWARE
        INFORMATION SYSTEMS, INC. AND SUBSIDIARIESCONSOLIDATED
        STATEMENT OF CASH FLOWSFor the Six Months Ended
        December 31,(Amounts
        in Thousands, except Shares)For the
        Six Months Ended December 31,2000
      
      1999(Unaudited)
      
      (Unaudited)Cash Flows From Operating ActivitiesNet earnings (loss)
    $
    
    (1,156)
  
  $
  794Adjustments to
      reconcile net earnings (loss) tonet cash
      provided by operating activities:Depreciation and amortization
    
    
    1,533
    
    1,096Deferred tax benefit
    
    
    (771)
    
    -Shares
      issued to directors
    
    
    50
    
    50Compensatory stock options
    
    
    -
    
    11Loss
      on disposal of fixed assets
    
    
    
    
    -Provision for doubtful accounts
    
    
    652
    
    99Changes in
      operating assets and liabilities:Accounts receivable
    
    
    (1,081)
    
    (329)Inventories
    
    
    22
    
    (72)Prepaid expenses and other assets
    
    
    129
    
    103Accounts payable, accrued expenses andcustomer advances
    
    
    413
    
    314Net cash (used in)
      provided by operating activities
    
    
    (209)
    
    2,066Cash Flows From Investing
      ActivitiesAcquisition of fixed assets, net of disposals
      
      
      (295)
      
      (305)Capitalized software costs
      
      
      (2,141)
      
      (1,793)Acquisition of technology
      
      
      
      
      
      (785)Net
        cash used in investing activities
      
      
      (2,436)
      
      
      (2,883)Cash Flows From Financing
      ActivitiesRepayment of debt
      
      
      -
      
      (158)Proceeds from exercise of options
      
      
      129
      
      909Other
      
      
      -
      
      -Net
        cash provided by (used in) financing activities
      
      
      129
      
      751Foreign currency translation adjustments
      
      
      (16)
      
      (25)Net
        increase in cash and cash equivalents
      
      
      (2,532)
      
      (91)Cash
        and cash equivalents at beginning of year
      
      
      3,634
      
      3,556Cash
        and cash equivalents at end of year
      $
      
       
;
        1,102
      $
      3,465==========
      
      ==========Supplemental disclosures of
      cash flow information:Cash paid
        during the period for:Interest
      $
      
      -
      $
      94Income taxes
      $
      
      7
      $
      127Non cash
        investing activities:Accounts
        payable related to the purchase of technology
      
      
      -
      $
      750See Notes
          to Consolidated Financial Statements.


---





MEDIWARE INFORMATION SYSTEMS, INC., AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANICIAL STATEMENTS



1.     FINANICIAL STATEMENTSIn the opinion of management, the accompanying unaudited, consolidated, condensed financial statements contain all adjustments necessary to present fairly the financial position of the Company and its results of operations and cash flows for the
interim periods presented. Such financial statements have been condensed in accordance with the applicable regulations of the Securities and Exchange Commission ("SEC") and therefore, do not include all disclosures required by generally accepted
accounting principles. These financial statements should be read in conjunction with the Company's audited financial statements for the year ended June 30, 2000 included in the Company's annual report filed on Form 10-K.

The results of operations for the three and six months ended December 31, 2000 are not necessarily indicative of the results to be expected for the entire fiscal year.

2.     EARNINGS (LOSS) PER SHARE

Basic earnings (loss) per share have been computed using the weighted average number of shares of common stock of the Company outstanding for each period presented. For the three and six months ended December 31, 2000, common stock
equivalents are not included in the calculation of loss per share as the effect would be anti-dilutive. For the three and six months ended December 31, 1999, the dilutive effect of stock options and other common stock equivalents is included in the
calculation of diluted earnings per share using the treasury stock method.

3.     NOTES PAYABLE TO A RELATED PARTY

On October 11, 2000, Fratelli Auriana, an entity controlled by Mr. Auriana, the Chairman of the Board of the Company, committed to loan the Company up to $2,000,000, to be drawn in multiples of $250,000, as needed by the Company,
subject to the terms described as follows. Mr. Auriana has agreed to provide funds to Fratelli Auriana should any be necessary to ensure Fratelli Auriana meets this obligation to the Company. Interest at the rate of prime plus 1/4% will be charged on any
outstanding balance and must be paid quarterly. Any principal and interest outstanding must be paid by September 30, 2002. Any money borrowed may be prepaid without penalty on three days notice. Any principal and interest outstanding will become
immediately due and payable upon a "change of control" of the Company, which has been defined in final agreements between Fratelli Auriana and the Company. The loan will be secured by all of the assets of the Company. The Company will pay Fratelli Auriana
an origination fee equal to the reasonably incurred expenses of Fratelli Auriana, including legal fees, up to a maximum of 3/8% of $2,000,000. There will be no facility fee. In connection with the loan from Fratelli Auriana, Mr. Auriana has agreed to
defer payment of principal and accrued interest on an existing demand loan extended by Mr. Auriana to the Company of approximately $704,000, which with accrued interest totaled $1,236,000 and $1,269,000 at June 30, 2000 and December 31, 2000,
respectively, until the same time as the loan from Fratelli Auriana to the Company becomes due. This earlier loan by Mr. Auriana to the Company shall maintain its present secured position. Terms and conditions were finalized and signed December 1, 2000
between Fratelli Auriana, Mr. Auriana and the Company. As of February 14, 2001, the Company has not borrowed against the loan.



INDEPENDENT ACCOUNTANTS' REPORT

To The Board of Directors and Stockholders of 
Mediware Information Systems, Inc.

We have reviewed the accompanying consolidated balance sheet of Mediware Information Systems, Inc. and subsidiaries as of December 31, 2000, and the related consolidated statements of operations and comprehensive income, and cash flows for the
three-month and six-month periods then ended. These financial statements are the responsibility of the Company's management.
We conducted our review in accordance with standards established by the American Institute of Certified Public Accountants. A review of interim financial information consists principally of applying analytical procedures to financial data and making
inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with generally accepted auditing standards, the objective of which is the expression of an opinion regarding the
financial statements taken as a whole. Accordingly, we do not express such an opinion.
Based on our review, we are not aware of any material modifications that should
be made to the accompanying financial statements for them to be in conformity
with generally accepted accounting principles.
We previously audited, in accordance with generally accepted auditing standards,
the consolidated balance sheet as of June 30, 2000, and the related consolidated
statements of operations and comprehensive income, stockholders' equity, and cash flows for the year then ended (not presented herein), and in our report dated September 1, (with respect to Notes 7 and 14, October 11, 2000), we expressed
an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying consolidated balance sheet as of June 30, 2000, is fairly stated in all material respects, in relation to the
consolidated balance sheet from which it has been derived.



Richard A. Eisner & Company, LLP

New York, New York
February 13, 2001



ITEM 2.        MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL 
                    CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

Certain statements made in or incorporated into this 10-Q may constitute "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, as the same may be amended from time to time (the
"Act") and in releases made by the SEC from time to time. Such forward-looking statements are not based on historical facts and involve known and unknown risks, uncertainties and other factors which may cause the actual results of the Company to be
materially different from any future results expressed or implied by such forward-looking statements. These risks and uncertainties include: (i) fluctuations in quarterly operating results, (ii) reliance on third party software, (iii) dependence on third
party marketing relationships, (iv) changes in the healthcare industry, (v) significant competition, (vi) the Company's ability to manage its rapid growth, (vii) the effects of government regulations on the Company, (viii) product related liabilities,
(ix) risks associated with system errors and warranties. Amplification of such risks may be found in the "Management's Discussion and Analysis of Financial Condition and Results of Operations" section of the Company's Annual Report on Form 10-K for the
fiscal year ended June 30, 2000. The Company does not intend to update publicly any forward-looking statements.

Results of Operations

Total Company revenues decreased by 14.2% or $1,005,000 and 13.4% or $1,884,000 for the three and six months ended December 31, 2000, respectively, as compared to the same periods a year ago. In comparing these periods, service
revenues accounted for 77.1% and 49.7% of total revenue declines for the three and six months ended December 31, 2000. This decline is principally a result of a loss of the increase in spending by the Company's customers in Fiscal 2000 in anticipation of
Y2K issues. For both the quarter and year to date results, increased system revenues in the Operating Room division were offset by declining revenues in the Blood Bank division.

System sales decreased 11.2% or $230,000 and 21.6% or $947,000 for the quarter and year-to-date periods compared to fiscal 2000. These decreases in system sales were principally due to a decline in Blood Bank systems revenues, which
were offset by gains in the OR Division. Management believes,but cannot assure that, the Blood Bank division systems revenues will trend up over the next few quarters through sales of its LifetrakTM product, depending on certain circumstances.

Service revenues, which include recurring software support, implementation and training services, decreased 15.5% or
$775,000 for the quarter and 9.7% or $937,000 for the six months compared to last year. Primarily, these decreases occurred in the company's Pharmacy division due to decreased levels of implementation activity principally as a result of the loss that
occurred in Fiscal 2000 in anticipation of potential Y2K issues. Management believes,but cannot assure that, these revenues will increase in the future due to the strengthening of system order potentials within the Pharmacy division, depending on certain
circumstances.

Cost of systems includes the cost of computer hardware and sublicensed software purchased from computer and software manufacturers by Mediware as part of its complete system offering. These costs can vary as the mix of revenue varies
between high margin proprietary software and lower margin computer hardware and sublicensed software components. Cost of systems was 29.6% of related system sales for the second quarter and 28.8% year to date compared to 40.9% and 35.5% for the same
periods last year. The decrease in cost of systems was primarily due to a higher mix of proprietary software and reduced Third Party software and hardware expense related to Y2K revenues in corresponding periods in Fiscal 2000.

Cost of services includes the salaries of client service personnel and communications expenses along with the direct client service department expenses. Cost of services increased by $172,000 or 11.3% for the second quarter and
$261,000 or 8.4% year to date compared to the same periods in fiscal 2000. As a percent of related service revenues, cost of services increased to 40.2% from 30.5% for the second quarter and to 38.5% from 32.0% year-to-date. The increase in cost primarily
reflects an increase in technical field installation and customer support activities. Management believes, but cannot assure, that these relative costs (e.g. as a percentage of related revenues) will improve as utilization rates, defined as the percentage
of billed hours to worked hours, increase resulting from the before mentioned strengthening of systems order potentials.

Software development costs include salaries, consulting, documentation, office and other related expenses incurred in product development along with amortization of software development costs. Software development costs increased 33.0%
for the quarter ended December 31, 2000 to $1,315,000 and 29.4% for the six months ended December 31, 2000 to $2,731,000 compared to the same periods last year. Total expenditures for software development, including both capitalized and non-capitalized
portions and excluding capitalized software amortization were $1,858,000 and $4,124,000, respectively, for the three and six months ended December 31, 2000 compared to $1,634,000 and $3,332,000 in fiscal 2000. The higher spending primarily reflects
increased development costs for both the Pharmacy Division's WORx product line and the Company's core blood bank product offerings.

Selling, general and administrative (SG&A) expenses include marketing and sales salaries, commissions, travel and advertising expenses. Also included is bad debt expense; legal, accounting and professional fees; salaries and bonus
expenses for corporate, divisional, financial and administrative staffs; utilities, rent, communications and other office expenses; and other related direct administrative expenses. SG&A expenses for the quarter ended December 31, 2000, included a
severance related charge of $530,000 due to a transition of senior management. This change, along with the company's plan to gain efficiencies through staff reduction in the Company's legacy products operational activities, is targeted to reduce overall
expense levels. Management believes, but cannot assure, that these efficiencies will result in a significant reduction of overall company expense starting in the third quarter and continuing through the fourth quarter of Fiscal 2001, depending on certain
circumstances. These savings are expected to be partially offset by increased spending in development projects anticipated to shorten product release dates. SG&A increased $882,000 or 29.1% to $3,916,000 for the quarter ended December 31, 2000,
compared to last year at $3,034,000. For the six months ended December 31, 2000, selling, general and administrative expenses increased $968,000 or 15.9% to $7,047,000.

Excluding the above mentioned $530,000 severance related charge, SG&A increased by $352,000 and by $438,000 for the three and six months ended December 31, 2000. This increase was principally due to increased bad debt expenses.

Net losses were $846,000 for the quarter. For the six months ended December 31, 2000, net losses increased
$1,950,000 to a loss of $1,156,000 compared to net earnings of $794,000 for the six months ended December 31, 1999.



Liquidity and Capital Resources

As of December 31, 2000 the Company had cash, and cash equivalents of $1,102,000, a decrease of $2,532,000 from the fiscal year ended June 30, 2000. In addition, the Company had borrowing capacity of $2,000,000 as of December 31,
2000. The Company's working capital deficit was
$(3,972,000) and current ratio was 0.66:1 at December 31, 2000, compared to a working capital deficit of $(1,343,000) and a current ratio of 0.88:1 at June 30, 2000. The Company's net cash outflow of $209,000 from operating activities for the six months
ended December 31, 2000 compares to a net cash inflow during the same period in fiscal year 2000 of $2,066,000. The change in working capital resulted from a $209,000 cash outflow from operations in addition to the $2,141,000 invested in capitalized
software and $295,000 invested in fixed asset acquisitions.

The Company invested $2,436,000 and $2,883,000 during the six months ended December 31, 2000 and 1999 respectively. The principal uses of cash for investing activities during the first six months of Fiscal 2001 included purchases of
fixed assets and investments in product development. Fixed asset purchases of $295,000 were primarily related to the relocation of the Hemocare product center and equipment purchased for development in the Blood Bank division. Additionally, the Company
acquired software and hardware to upgrade the Company's accounting and time-tracking systems. Further, in the first six months of Fiscal 2000, the company paid $750,000 towards the purchase of the LifeTrak(TM) blood center software package. The Company
capitalized $2,141,000 and $1,793,000 of product development costs during the quarters ended December 31, 2000 and 1999, respectively. The product development capitalized related to continuing new development in the Pharmacy, Operating Room and Blood Bank
divisions. The Company plans to continue on a plan of investing heavily to develop all its core product lines in current technologies.

Cash generated in financing activities for the six months ended December 31, 2000 of $129,000 related to proceeds from the exercise of options and warrants compared to $909,000 generated in the same period a year ago. During the first
six months quarter of fiscal year 2000, $158,000 was used to repay debt obligations.

The Company's liquidity is influenced by the Company's ability to perform on a "best of breed" basis in a competitive industry that is currently impacted by consolidations of Healthcare Information System providers. The factors that
may affect liquidity are the ability to penetrate the market with its products, maintain or reduce the length of the selling cycle, and the ability to collect cash from clients as implementations of systems progresses. Exclusive of activities involving
any future acquisitions of products or companies that compliment or augment the existing line of products, management believes that current funds, cash generated from operations, and the loan commitment from Fratelli Auriana, an entity controlled by
Lawrence Auriana, the Chairman of the Board of Directors of the Company, described above in Note 3 to the Financial Statements, and anticipated expense reductions, will be sufficient to meet operating requirements for the remainder of fiscal year 2001.
The Company continues to review its long term cash needs. Currently, there are no plans for additional outside financing.



ITEM 3.      QUANTITATIVE AND QUALITATIVE DISCLOSURES
                   ABOUT MARKET RISKS

The Company does not currently have any material exposure to foreign currency transaction gains or losses. However, the company does have some exposure to foreign currency rate fluctuations arising from sales made to customers in
the United Kingdom. These transactions are made by the Company's U.K. based, wholly owned subsidiary which transacts business in the local functional currency. To date, the Company has not entered into any derivative financial instrument to manage foreign
currency risk and is currently not evaluating the future use of any such financial instruments.

ITEM 5.      OTHER INFORMATION

Effective January 14, 2001, George "Bud" Barry has been appointed President and Chief Executive Officer and a member of the Board of Directors, replacing Michael Montgomery who resigned to resume other business interests that he
had put on hold to help Mediware through the important general management transformation. Mr. Montgomery successfully completed that management transformation and several important operational goals during his tenure.

ITEM 6.      EXHIBITS AND REPORTS ON FORM 8-K

(a).           Exhibits

|Exhibit 11.         | Schedule of Computation of Net Income (Loss) Per Share                                                                              
|------------------- | ------------------------------------------------------------------------------------------------------------------------------------
|Exhibit 15.         | Letter of awareness from Richard A. Eisner & Company, LLP dated February 14, 2001 concerning unaudited interim financial information
|Exhibit 27.         | Financial Data Schedule                                                                                                             
|(b).                | Reports on Form 8-K                                                                                                                 
|Reports on Form 8-K | No reports on Form 8-K were filed by the Company during the quarter ended December 31, 2000                                         







SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
                                          
    MEDIWARE INFORMATION SYSTEMS, INC.                                         
                              (Registrant)



February 14, 2000                              GEORGE J. BARRY        Date                                 
                   GEORGE J. BARRY
                                          
                          PRESIDENT AND CHIEF EXECUTIVE OFFICER



February 14, 2000                                JILL H. SUPPES        Date                                 
                   JILL H. SUPPES
                                          
                         CHIEF ACCOUNTING OFFICER





# 

---

EXHIBIT 11

MEDIWARE
        INFORMATION SYSTEMS, INC. AND SUBSIDIARIESComputation
        of Net Earnings Per ShareThree
        months Ended December 31,
      
      Three
        months Ended December 31,
      
      Six
        months Ended December 31,
      
      Six
        months Ended December 31,2000
      
      1999
      
      2000
      
      1999(Unaudited)
      
      (Unaudited)
      
      (Unaudited)
      
      (Unaudited)Basic Earnings Per ShareNet earnings (loss)
      
      $
      (846,000)
      $
      433,000
      $
      (1,156,000)
      $
      794,000Weighted-average shares:Outstanding
      
      
      7,166,000
      
      6,344,000
      
      7,141,000
      
      6,258,000Basic Earnings Per
        Share
      
      $
      (0.12)
      $
      0.07
      $
      (0.16)
      $
      0.13Diluted Earnings Per ShareNet earnings (loss)
      
      $
      (846,000)
      $
      433,000
      $
      (1,156,000)
      $
      794,000Weighted-average shares:Outstanding
      
      
      7,166,000
      
      6,344,000
      
      7,141,000
      
      6,258,000Options and Warrants
      
      
      -
      
      857,000
      
      -
      
      918,0007,166,000
      
      7,201,000
      
      7,141,000
      
      7,176,000Diluted Earnings Per
        Share
      
      $
      (0.12)
      $
      0.06
      $
      (0.16)
      $
      0.11


---



EXHIBIT 15

To the Board of Directors and Stockholders of 
Mediware Information Systems, Inc.
We have reviewed, in accordance with standards established by the American Institute of Certified Public Accountants, the unaudited interim consolidated financial statements of Mediware Information Systems, Inc. and subsidiaries as of December 31, 2000
and for the three and six month periods then ended, as indicated in our report dated February 13, 2001; because we did not perform an audit, we expressed no opinion on those financial statements.

We are aware that our review report, which is included in your Quarterly Report on Form 10-Q for the quarter ended December 31, 2000, is incorporated by reference in the Registration Statement on Form S-8 (No. 333-07591).
We are also aware that our review report, pursuant to Rule 436(c) under the Securities Act of 1933, is not considered a part of the Registration Statement prepared or certified by an accountant or a report prepared or certified by an accountant within
the meaning of Section 7 and 11 of that Act.

Richard A. Eisner & Company, LLP

New York, New York
February 13, 2001



EXHIBIT 27

Mediware Information Systems, Inc., and Subsidiaries

Financial Data Schedule (Six Months Ended December 31, 2000 Form 10-Q)

THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM MEDIWARE'S QUARTERLY REPORT TO SHAREHOLDERS FOR THE QUARTER ENDED DECEMBER 31, 2000 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.



|MULTIPLIER 1,000                   |          
|---------------------------------- | ---------
|PERIOD TYPE                        | 6-MOS    
|FISCAL YEAR END                    | 6/30/2001
|PERIOD START                       | 7/01/2000
|PERIOD END                         | 12/31/000
|CASH AND CASH EQUIVALENTS          | 1102     
|MARKETABLE SECURITIES              | 0        
|ACCOUNTS RECEIVABLE - TRADE- TRADE | 6826     
|ALLOWANCES FOR DOUBTFUL ACCOUNTS   | 600      
|INVENTORY                          | 192      
|TOTAL CURRENT ASSETS               | 7747     
|PROPERTY, PLANT AND EQUIPMENT      | 5461     
|ACCUMULATED DEPRECIATION           | 3320     
|TOTAL ASSETS                       | 28389    
|TOTAL CURRENT LIABILITIES          | 11719    
|BONDS, MORTGAGES AND SIMILAR DEBT  | 1269     
|PREFERRED STOCK - MANDATORY        | 0        
|PREFERRED STOCK - NOT MANDATORY    | 0        
|COMMON STOCK                       | 717      
|OTHER STOCKHOLDERS' EQUITY         | 14684    
|TOTAL LIABILITIES AND EQUITY       | 28389    
|SALES                              | 12173    
|TOTAL REVENUES                     | 12173    
|COST OF GOODS SOLD                 | 4349     
|TOTAL COSTS AND EXPENSES           | 14127    
|OTHER COSTS AND EXPENSES           | 0        
|PROVISION FOR DOUBTFUL ACCOUNTS    | 0        
|INTEREST EXPENSE                   | 32       
|INCOME LOSS BEFORE INCOME TAXES    | (1,927)  
|INCOME TAX BENEFIT PROVSION        | 771      
|INCOMELOSS CONTINUING OPERATIONS   | (1,156)  
|DISCOUNTINUED OPERATONS            | 0        
|EXTRAORDINARY ITEMS                | 0        
|CHANGE IN ACCOUNTING               | 0        
|NET LOSSINCOME                     | (1,156)  
|INCOMELOSS PER SHARE - PRIMARY     | (.16)    
|LOSSINCOME PER SHARE - DILUTED     | (.16)